GlassScriptPhysician profile
Kristina Mullen
NPI 1124505706
$8,394.28
in general payments reported to CMS, 2019-2025
24 companies · $751 in 2025
The $751 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,347 · 2022: $2,179 · 2023: $2,234 · 2024: $1,883 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,868.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.47 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,043.26 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $923.02 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $650.57 | 2021-2025 | Rexulti, Abilify Mycite |
| Alkermes, INC. | $454.92 | 2021-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $397.03 | 2022-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $384.03 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $348.73 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $342.26 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $317.65 | 2022-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $253.53 | 2022-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $224.86 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $217.51 | 2022-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $176.70 | 2023 | Auvelity |
| Corium, LLC | $154.53 | 2023-2024 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $116.36 | 2021 | |
| Vanda Pharmaceuticals INC. | $100.81 | 2022-2025 | Fanapt |
| Bioxcel Therapeutics, INC. | $90.32 | 2023 | Igalmi |
| Noven Therapeutics, LLC | $73.08 | 2023-2024 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $68.65 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.34 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $34.44 | 2023 | Belsomra |
| Neos Therapeutics, LP | $31.45 | 2021 | |
| Almatica Pharma LLC | $14.76 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.